Adc Therapeutics SA

ADC Therapeutics SA announced on June 30, 2026, the approval of one-time retention awards for certain employees, including named executive officers, comprising cash incentives and Restricted Stock Units (RSUs).

ADC Therapeutics is cutting 17% of its global workforce to streamline operations and focus resources on ZYNLONTA clinical milestones.

ADC Therapeutics announced topline data from its Phase 3 LOTIS-5 trial, showing ZYNLONTA in combination with rituximab met its primary endpoint for progression-free survival in relapsed or refractory diffuse large B-cell lymphoma.

ADC Therapeutics SA announced that all proposals submitted to shareholders at its 2026 annual general meeting on June 1, 2026, were approved, including financial statements and director reelections.

ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million, an increase from the prior year, while net loss narrowed to $33.0 million, driven by lower operating expenses.

ADC Therapeutics SA has amended its royalty agreement with HealthCare Royalty Management, LLC, revising change of control payments and issuing warrants for 9.8 million common shares.

ADC Therapeutics reported a 15.1% increase in net product revenue for Q1 2026, driven by higher sales volume and pricing, while R&D expenses decreased significantly due to restructuring.

ADC Therapeutics reported a wider net loss in Q3 2025, driven by restructuring costs, despite strong clinical trial data for ZYNLONTA and successful capital raises.

ADC Therapeutics reported a widened net loss in Q2 2025, driven by a strategic restructuring plan and increased R&D costs, despite a rise in ZYNLONTA product and license revenues.

ADC Therapeutics' Q1 2025 results show increased revenue driven by licensing milestones, alongside ongoing efforts to manage operating expenses and advance its ADC technology.

ADC Therapeutics reported its third quarter 2024 financial results, showing a slight increase in product revenue and a decrease in operating expenses.

ADC Therapeutics reported its second quarter 2024 financial results, showcasing a decrease in product revenue but progress in its clinical pipeline and research strategy.

ADC Therapeutics' 2024 10-K filing highlights the company's focus on expanding ZYNLONTA's market and advancing its solid tumor pipeline through strategic collaborations.

ADC Therapeutics SA, a Swiss stock corporation, outlines its share capital structure, registration rights agreements, and articles of association in its latest 10-K filing.

ADC Therapeutics SA reports an award of restricted stock units to Chief Medical Officer Mohamed Zaki, with vesting conditions tied to employment and time.

ADC Therapeutics SA reports an RSU award to Chief Legal Officer Peter J. Graham, with vesting conditions tied to continued employment and employment status.

ADC Therapeutics SA reports that Chief Financial Officer Jose Carmona was granted 203,700 Restricted Stock Units (RSUs) on June 30, 2026.

ADC Therapeutics SA reports a significant RSU award to CEO Ameet Mallik, vesting in June 2027.

Robert Azelby, a Director at ADC Therapeutics SA, reported transactions involving the acquisition of restricted stock units and the sale of common shares.

Director Ron Squarer reported transactions involving ADC Therapeutics SA common shares, including an annual grant of RSUs and withholding for tax obligations.

ADC Therapeutics SA announces its 2026 Annual General Meeting of Shareholders, to be held virtually on June 1, 2026, with key proposals including financial statement approval, compensation review, director reelections, and amendments to share capital.

ADC Therapeutics SA is holding its Annual General Meeting on June 3, 2025, seeking shareholder approval for proposals including financial statement approval, director elections, compensation matters, and an increase in conditional share capital.

ADC Therapeutics has scheduled its 2025 Annual General Meeting for June 3, 2025, to address key proposals including financial approvals, director elections, and executive compensation.

ADC Therapeutics is holding an extraordinary shareholder meeting to vote on proposals to increase the company's capital range and conditional share capital.

ADC Therapeutics is holding a special meeting to seek shareholder approval for amendments to its articles of association to increase its capital range and conditional share capital for financing, acquisitions, and other purposes.

ADC Therapeutics SA will hold its Annual General Meeting on June 13, 2024, to vote on proposals including the approval of financial statements, director re-elections, and compensation matters.

BlackRock, Inc. has disclosed beneficial ownership of 5.4% of ADC Therapeutics SA's common stock as of June 30, 2026.

Redmile Group, LLC has completed an internal reorganization of its holdings in ADC Therapeutics SA, maintaining a 9.9 percent beneficial ownership stake while shifting assets to a new subsidiary.

Redmile Group, LLC and Jeremy C. Green report a 9.9% beneficial ownership stake in ADC Therapeutics SA, including shares held through private investment vehicles and warrants.

Prosight Management, LP and affiliated entities have filed an Amendment No. 3 to Schedule 13G, disclosing beneficial ownership of 5.8% of ADC Therapeutics SA's common shares.

Oaktree entities report 4.14% beneficial ownership in ADC Therapeutics SA, while Brookfield entities cease to report beneficial ownership as part of the group.

Redmile Group, LLC and its affiliates have increased their beneficial ownership in ADC Therapeutics SA to 14.0% of common shares outstanding.